VEGFA and optic papillitis: VEGF plays a key role in neovascular AMD [9,10], and anti-VEGF agents, including bevacizumab, ranibizumab, aflibercept, brolucizumab and the dual-pathway anti-VEGF and angiopoietin-2 inhibitor faricimab, have been shown to inhibit the growth of neovascular lesions and resolve retinal oedema, resulting in positive visual outcomes [11,12,13,14,15,16].